Qlucore

Qlucore Competitive Intelligence & Landscape

qlucore.com ·

Qlucore
ForesightIQ Predictions

What is Qlucore likely to do next?

ForesightIQ connects Qlucore's hiring, product, web, ad, and market signals to forecast strategic moves — often months before they're announced.

Hiring signal

Senior hiring patterns point to a planned enterprise product line launching within two quarters.

High confidence · Next 1–2 quarters
Product signal

Quiet changes to docs and pricing pages signal an upcoming usage-based pricing tier and new API surface.

Likely · Next quarter
Market signal

Ad spend and partnership activity indicate a push into the mid-market segment across two new regions.

Plausible · Next 2–3 quarters
Qlucore Unlock Qlucore's predicted moves

Free · generated in ~60 seconds · no signup to preview

Overview

Qlucore Overview

Qlucore (qlucore.com) is a Swedish company specializing in advanced software for data analysis and cancer diagnostics, with a core mission to accelerate, simplify, and improve research and precision medicine through visualization-based analysis [qlucore.com]. Founded in 2007 by Magnus Fontes and Thoas [qlucore.com/founders], the company originated from a collaborative research project at Lund University, Sweden, addressing the challenge of conceptualizing vast amounts of high-dimensional data generated in fields like microarray gene expression analysis [qlucore.com/about]. Their headquarters are located in Lund, Sweden, with an additional office in New York, USA [qlucore.com/sites/default/files/2025-07/Bolagsordning%20-%20Qlucore%2020250731.pdf].

Qlucore's primary target market includes researchers and professionals in clinical diagnostics and companion diagnostics, particularly those involved in proteomics and qPCR data analysis [qlucore.com]. The company's main offerings include the Qlucore Omics Explorer, Qlucore Insights, and Qlucore Diagnostics software solutions [qlucore.com]. The Qlucore Omics Explorer, which recently released version 3.11, is designed to make complex data analysis easier and faster, catering to the expanding use of proteomics data driven by precision medicine and biomarker discovery [qlucore.com].

Carl-Johan Ivarsson has served as the CEO of Qlucore since 2007, bringing over 25 years of experience in software development, product management, and sales [qlucore.com/management-team]. The company is registered as Qlucore AB (publ) with registration number 556719-3528 [qlucore.com/evaluation-license].

Qlucore continuously works to reduce the cost of analyzing complex conditions, such as Cancer of Unknown Primary (CUP), through their innovative software [qlucore.com/news].

Competitors

Qlucore Competitors

Qlucore specializes in visualization-based bioinformatics software, accelerating precision medicine through intuitive data analysis for research and cancer diagnostics. The company, founded in 2007 by Johan Råde, Magnus Fontes, and Carl-Johan Ivarsson in Lund, Sweden, offers products like Qlucore Omics Explorer and Qlucore Insights, designed for various applications including data analysis, clinical diagnostics, and companion diagnostics. Its core strength lies in simplifying complex data, making advanced bioinformatics accessible to researchers and clinicians globally [https://stockanalysis.com/quote/sto/QCORE/company/].

One significant competitor to Qlucore in the bioinformatics space is Benchling. While Qlucore focuses heavily on visualization-based data analysis for omics data and clinical diagnostics, Benchling offers a broader R&D Cloud platform that includes electronic lab notebooks, LIMS, and molecular biology tools.

Benchling's comprehensive suite caters to a wider range of laboratory management needs, potentially attracting users looking for an integrated platform beyond just data analysis, a segment where Qlucore might offer more specialized, in-depth analytical tools for specific omics datasets [https://tracxn.com/d/companies/qlucore/__mFKqQmZByyOmKsevt4qfsCIxYGXwY32lFe5t012zNrI].

Another key player in the market is Thermo Fisher Scientific, a powerhouse in gene expression analysis.

Thermo Fisher Scientific offers an extensive portfolio including qPCR systems, RNA sequencing solutions, reagents, and platforms like Applied Biosystems and Ion Torrent. This broad offering and established market presence give them a significant competitive edge, covering both instrumentation and consumables in addition to analytical tools, a more comprehensive approach compared to Qlucore's software-centric focus [https://www.blogarama.com/business-blogs/290121-marketsandmarkets-blog-market-research/76765501-top-companies-gene-expression-analysis-driving-innovation-2026].

Illumina, Inc. also stands out as a major competitor, particularly in gene expression analysis, specializing in DNA sequencing and array-based technologies.

Illumina's platforms enable researchers to analyze gene expression at scale, complementing its dominant position in genomics. While Qlucore provides powerful tools for visualizing and exploring omics data, Illumina's strength lies in generating the foundational sequencing data, often a precursor to the type of analysis Qlucore facilitates, positioning them as providers of critical upstream technology [https://www.blogarama.com/business-blogs/290121-marketsandmarkets-blog-market-research/76765501-top-companies-gene-expression-analysis-driving-innovation-2026].

Finally, companies like QIAGEN are also prominent in the bioinformatics and life science market.

QIAGEN is known for its sample and assay technologies, offering integrated solutions for molecular testing. Similar to Thermo Fisher Scientific and Illumina, QIAGEN provides a broader range of products and services, including consumables and automation, which contrasts with Qlucore's more specialized software-only approach to data visualization and analysis. This broader scope allows QIAGEN to capture a wider market share by addressing multiple stages of the research and diagnostics workflow [https://www.blogarama.com/business-blogs/290121-marketsandmarkets-blog-market-research/76765501-top-companies-gene-expression-analysis-driving-innovation-2026].

Alternatives

Qlucore Alternatives

Product & Pricing

Qlucore Product and Pricing Intelligence

Qlucore offers specialized software solutions designed to accelerate, simplify, and improve research and cancer diagnostics through visualization-based analysis [qlucore.com]. Their product line includes Qlucore Omics Explorer, Qlucore Insights, and Qlucore Diagnostics [qlucore.com/how-it-works-products].

Qlucore Omics Explorer is a powerful, flexible, and easy-to-use visualization tool for multi-omics and NGS data analysis, providing immediate results and insights [qlucore.com/qlucore-omics-explorer]. It features a base module for essential multi-omics data analysis, including bulk RNA-seq and proteomics, with an optional NGS Module for extensive genome browser-centric analysis [qlucore.com/features].

Qlucore Omics Explorer is available in various configurations, including both local installations and multiple Cloud Packages [qlucore.com/cloud-packages]. The Cloud Services, operating securely within Amazon Web Services (AWS), enable users to access computational power and centralized data storage from any internet-connected device, offering enhanced flexibility for data analysis [qlucore.com/cloud-services, qlucore.com/news/qlucore-newsletter-new-cloud-option-for-more-flexible-data-analysis]. The Standard package for Qlucore Omics Explorer Cloud provides basic functionality for analyzing any omics data, including RNA-seq [qlucore.com/qlucore-omics-explorer-cloud-configuration].

For Qlucore Omics Explorer and Qlucore Insights, pricing details are not directly published on the website, but interested parties can request a personalized quote through a dedicated form [qlucore.com/get-a-quote, qlucore.com/get-a-qlucore-insights-quote]. During the license period, all users receive product updates, upgrades, and online support via web and email without additional charges [qlucore.com/get-a-quote, qlucore.com/get-a-qlucore-insights-quote].

Qlucore also offers special academic pricing to support research and education [qlucore.com/get-a-quote]. For Qlucore Insights, users can specify models of interest such as BCP-ALL, AML, Lung cancer, Urothelial cancer, and Gene fusion analysis models (hg19, hg38) when requesting a quote [qlucore.com/get-a-qlucore-insights-quote].

Hiring & Layoffs

Qlucore Hiring and Layoffs

Qlucore, a company founded in 2007, specializes in intuitive bioinformatics software for research and companion diagnostics, with a mission to simplify the analysis of complex genomic and proteomic data. Their solutions are designed to accelerate, simplify, and improve research and cancer diagnostics through visualization-based analysis. The company's commitment to innovation in precision medicine and AI-based software for more accurate diagnostics suggests a strategic focus on expanding its technological capabilities and market reach.

While specific recent hiring trends or layoff announcements are not explicitly detailed on the Qlucore website, the company consistently highlights career opportunities, indicating an ongoing need for talent. The "Careers" page positions Qlucore as a leading provider of next-generation bioinformatics software, implying a continuous demand for skilled professionals to support their mission and product development [qlucore.com/vacancies]. Their presence in approximately 25 countries also suggests a global operational structure that would necessitate various roles.

The absence of specific job listings but the presence of a dedicated "Careers" page and information about a long-term incentive program for employees in 2022 [qlucore.com/sites/default/files/2023-09/Notice%20Annual%20General%20Meeting%20in%20Qlucore%20AB%2020220920.pdf] indicates a strategy focused on employee retention and growth within the company. Furthermore, Qlucore actively engages in collaborations with scientific experts to develop disease-specific classifier models [qlucore.com/collaborations-and-partners] and offers various training events and webinars [qlucore.com/events], which could signal an investment in internal expertise and client education. This long-term view on employee value and strategic partnerships suggests a stable and growth-oriented hiring pattern, prioritizing specialized skills in bioinformatics, software development, and precision diagnostics.

Leadership

Qlucore Management and Leadership Team

Qlucore, a company specializing in visualization-based analysis for precision medicine and cancer diagnostics, is led by an experienced management team and a robust board of directors.

Carl-Johan Ivarsson, a Master of Science in Electrical Engineering from Lund University of Technology, has been the CEO of Qlucore since 2007. With over 25 years of experience in software development, product management, and sales, Ivarsson previously held the position of Vice President responsible for product management at Ericsson Mobile Platforms, bringing significant industry expertise to his role at Qlucore [https://qlucore.com/management-team]. He is also the primary investor relations contact for the company [https://qlucore.com/investor-relation-contact].

The Qlucore Board of Directors plays a crucial role in the company's governance.

Lars Pålsson, holding an M.Sc. in Electrical Engineering, serves as the Chairman of the Board. Pålsson has extensive experience in managing IT companies, including an eight-year tenure as Chairman and CEO of MultiQ. He is also active as a business angel through his family office, Mikrolund, and holds a significant number of shares in Qlucore through a controlled company [https://qlucore.com/board-of-directors].

Qlucore's governance structure, as detailed in its corporate governance framework, outlines the distribution of responsibility between shareholders, the board, and the CEO [https://qlucore.com/bolagsstyrning]. The company’s origins as a collaborative research project at Lund University involved researchers from the Departments of Mathematics and Clinical Genetics, with Magnus Fontes and Thoas Fioretos being among the founders in 2007 [https://qlucore.com/about, https://qlucore.com/founders]. These founders also contribute to the company's strategic direction as members of the Scientific Advisory Board, which includes independent senior scientists and industry experts to provide guidance on scientific results, technology trends, and future product roadmaps [http://qlucore.com/scientific-advisory-board].

Financials

Qlucore Financial Performance, Fundraising, M&A

Qlucore AB (publ), a Swedish public limited company founded on December 5, 2006, operates in the field of advanced data processing software and related services [qlucore.com/modules/custom/qlucore_ipo/qlucore-prospekt_8_oktober_2021.pdf]. The company maintains a transparent financial reporting schedule, with interim and year-end reports regularly published [http://qlucore.com/financial-calendar]. These financial reports, along with other investor relations information, are accessible directly on their website [qlucore.com/financial-reports].

Qlucore has actively pursued fundraising to support its growth and international expansion. In a pre-IPO private placement, the company secured SEK 30 million (USD 3.5 million) to accelerate sales activities and expand its technical team in preparation for an initial public offering [qlucore.com/sites/default/files/2021-03/Qlucore%20secures%20SEK%2030%20million%20(USD%203.5m)%20for%20international%20expansion.pdf]. This strategic investment was intended to occur within twelve months of the announcement.

Further demonstrating its commitment to growth, Qlucore also raised investment in 2012 to fund product development and facilitate entry into the USA market. This funding supported the expansion of their R&D and product development team in Sweden and the establishment of a new sales office in the USA [qlucore.com/news/qlucore-raises-investment-for-international-expansion]. The company, led by CEO Carl-Johan Ivarsson [qlucore.com/investor-relation-contact], is focused on developing and licensing software for advanced data processing, along with providing support, training, and specialist consulting services [qlucore.com/sites/default/files/2025-07/Bolagsordning%20-%20Qlucore%2020250731.pdf].

Partnerships

Qlucore Partnerships, Clients and Vendors

Qlucore fosters key collaborations and partnerships to enhance its precision medicine solutions, extending research capabilities through integrations with other leading analysis tools and service providers [qlucore.com/collaborations-and-partners]. Notably, Qlucore partners with Clarivate to combine Qlucore Omics Explorer (QOE) with MetaCore™, enabling faster and more precise analysis for deeper biological insights [qlucore.com/combine-qlucore-omics-explorer-and-metacoretm]. Furthermore, Qlucore teamed up with Nebion to facilitate the combination of Qlucore Omics Explorer and Genevestigator, providing an end-to-end solution for RNA-seq gene expression data analysis [qlucore.com/news/qlucore-and-nebion-team-up-to-deliver-improved-analysis-options-0]. These strategic alliances ensure that Qlucore's offerings are robust and interoperable within the broader scientific ecosystem, including integration with NDEx Integrated Query for enhanced gene set interpretation and biological network building [qlucore.com/video/use-ndex-integrated-query-together-with-qlucore-omics-explorer].

Qlucore also works closely with scientific experts and key opinion leaders to develop disease-specific classifier models for both clinical diagnostics (Dx) and companion diagnostics (CDx) [qlucore.com/collaborations-and-partners]. A significant client example is Rigshospitalet, Denmark’s largest teaching and public hospital, which has implemented Qlucore Insights for in-house diagnostics, particularly for pediatric Acute Lymphoblastic Leukemia (ALL) [qlucore.com/case/qlucore-insights-for-diagnostics-of-pediatric-all]. Rigshospitalet’s successful validation and subsequent clinical use of Qlucore Diagnostics BCP-ALL, a CE-marked (IVDR) software, underscores Qlucore's impact in advancing clinical laboratories across Europe [qlucore.com/news/qlucore-newsletter-ivdr-test-for-pediatric-leukemia-now-in-clinical-use, qlucore.com/qlucore-diagnostics].

Enterprise clients utilizing Qlucore's software have made significant contributions to scientific literature, with thousands of articles published in high-impact journals, including Nature, over recent years [qlucore.com/news/qlucore-newsletter-together-we-are-shaping-the-future-of-research]. Beyond clinical diagnostics, Qlucore Omics Explorer is employed by research institutions globally, such as The Center for Interdisciplinary Cardiovascular Sciences (CICS) in Boston, a collaboration between Brigham and Women's Hospital and Kowa Company Ltd., for proteomics data analysis to understand cardiovascular disease [qlucore.com/cs_proteomics]. Similarly, the National Institute of Nutrition and Seafood Research (NIFES) in Norway utilizes Qlucore Omics Explorer for studying molecular mechanisms related to environmental contaminants and their interaction with nutrients [qlucore.com/case/analyzing-proteomics-and-transcriptomics-data]. These diverse applications highlight Qlucore's role in empowering cutting-edge research and diagnostics across various scientific domains.

Events

Qlucore Event Participations

Qlucore actively engages its community and fosters expertise through a comprehensive calendar of webinars and events. These offerings encompass both online and in-person sessions, catering to a diverse audience ranging from new users to advanced data analysts [qlucore.com/webinars-and-events]. The company prioritizes providing educational materials and training, ensuring users can maximize their understanding and utilization of Qlucore Omics Explorer and Qlucore Insights for research and diagnostics [qlucore.com/news/qlucore-newsletter-free-trainings-available-at-some-of-europes-leading-research-hubs].

Qlucore frequently hosts training events at prominent research hubs across Europe. Recent and upcoming in-person training sessions have included locations such as the University of Cambridge in the UK and the University of Copenhagen in Denmark, offering both basic and advanced training modules [qlucore.com/events]. These sessions are often free and highly recommended, focusing on practical, hands-on experience to help participants get better answers from their data using Qlucore Omics Explorer [qlucore.com/news/qlucore-newsletter-free-trainings-available-at-some-of-europes-leading-research-hubs]. Additionally, Qlucore organizes European Lunch Seminars that delve into topics like the easy and simple stratification and classification of tumor samples using Qlucore Insights [qlucore.com/news/qlucore-newsletter-easy-and-simple-stratification-and-classification-of-tumor-samples-using].

Beyond in-person events, Qlucore maintains a robust schedule of webinars, covering a wide array of topics related to data analysis and precision diagnostics. Examples include webinars on Qlucore Omics Explorer features like various plot types for data visualization [qlucore.com/webinar/0d4225445aa1416fa1b5fe456c00dbed], and specialized sessions for Qlucore Insights focusing on enhancing bladder cancer molecular classification [qlucore.com/webinar/377b3ecbbc14410cb5ff7826b1c45a19] or a new lung cancer classification model [qlucore.com/video/webinar-qlucore-insights-new-lung-cancer-classification-model]. The company also offers webinars on more general data analysis techniques, such as working with proteomics and metabolomics data [qlucore.com/video/webinar-proteomics-and-metabolomics-data-analysis], and specific product updates like the Qlucore Diagnostics CE-marked test for improved leukemia classification [qlucore.com/webinar].

For those unable to attend scheduled events, Qlucore provides the flexibility of personal webinars, allowing individuals to discuss specific software-related topics or receive tailored training [qlucore.com/webinar]. Furthermore, a comprehensive library of previous webinars is available for on-demand viewing, ensuring continuous access to valuable educational content and demonstrations of Qlucore's innovative solutions [qlucore.com/webinar/0d4225445aa1416fa1b5fe456c00dbed]. This commitment to diverse event participation underscores Qlucore's dedication to supporting its users and advancing the field of precision medicine.

Frequently Asked Questions

What is Qlucore's strategic approach to expanding its market reach, particularly in diagnostics?

Qlucore is strategically expanding its market reach by developing disease-specific classifier models through collaborations with scientific experts for clinical (Dx) and companion diagnostics (CDx). A key example is their partnership with Rigshospitalet in Denmark, which implemented Qlucore Insights for pediatric Acute Lymphoblastic Leukemia (ALL) diagnostics, showcasing their impact in advancing clinical laboratories.

What do Qlucore's recent partnerships with Clarivate and Nebion signal about their product strategy?

Qlucore's partnerships with Clarivate (for MetaCore™) and Nebion (for Genevestigator) signal a product strategy focused on enhancing interoperability and providing end-to-end solutions. These collaborations aim to integrate Qlucore Omics Explorer with other leading analysis tools, enabling faster, more precise analysis and deeper biological insights for users working with RNA-seq and other omics data.

What does Qlucore's extensive webinar and event schedule indicate about their customer engagement and product development priorities?

Qlucore's robust schedule of webinars, training events, and personal consultations indicates a strong commitment to customer engagement and education. This strategy likely aims to maximize user proficiency with Qlucore Omics Explorer and Qlucore Insights, focusing on practical, hands-on experience and addressing specific data analysis challenges, thereby fostering expertise in precision medicine and diagnostics.

What do Qlucore's funding activities, specifically the pre-IPO private placement and 2012 investment, suggest about their growth ambitions?

Qlucore's funding activities, including a SEK 30 million (USD 3.5 million) pre-IPO private placement and a 2012 investment, suggest a clear ambition for international growth and product development. These funds were specifically allocated to accelerate sales, expand the technical team, and establish a sales office in the USA, indicating a strategic focus on scaling operations and market presence.

How does Qlucore's leadership team's background influence the company's strategic direction in bioinformatics?

Qlucore's leadership, particularly CEO Carl-Johan Ivarsson with over 25 years in software development and product management at Ericsson, brings deep industry experience to the company. This background, combined with founders from Lund University's research in mathematics and clinical genetics, likely guides Qlucore's strategic direction towards intuitive, visualization-based bioinformatics software for precision medicine and cancer diagnostics.

What competitive advantages does Qlucore seek to leverage given the broader offerings of competitors like Benchling and Thermo Fisher Scientific?

Qlucore leverages its specialization in visualization-based omics data analysis to gain a competitive advantage against broader offerings from companies like Benchling (R&D Cloud platforms) and Thermo Fisher Scientific (instrumentation, consumables, and analytical tools). Qlucore focuses on providing in-depth, intuitive analytical tools for specific omics datasets, aiming for specialized expertise rather than a comprehensive lab management suite or upstream data generation.

What is the strategic rationale behind Qlucore offering cloud packages for Omics Explorer?

Qlucore's strategic rationale behind offering cloud packages for Omics Explorer is to provide enhanced flexibility, computational power, and centralized data storage for users. By operating securely within Amazon Web Services (AWS), they enable access from any internet-connected device, addressing the growing need for scalable and accessible data analysis solutions in research and diagnostics.

Does Qlucore's hiring strategy, despite a lack of specific job listings, indicate stability or aggressive expansion?

Qlucore's hiring strategy, characterized by a dedicated 'Careers' page and a long-term incentive program for employees, suggests a stable, growth-oriented approach rather than aggressive expansion. The company appears to prioritize employee retention, internal expertise, and strategic partnerships, indicating a focus on steady development in bioinformatics, software, and precision diagnostics.

What does the existence of academic pricing and free training events indicate about Qlucore's market positioning and long-term strategy?

Qlucore's offering of academic pricing and free training events signals a strategy focused on permeating the academic and research sectors. This approach likely aims to cultivate early adoption of their software, build brand loyalty among future professionals, and ensure a continuous pipeline of users familiar with Qlucore's tools, thereby securing long-term market positioning in scientific research.

How does Qlucore differentiate its Omics Explorer from alternatives like mixOmics Pro in the multi-omics analysis space?

Qlucore differentiates its Omics Explorer through its focus on powerful, flexible, and easy-to-use visualization for immediate results and insights across multi-omics and NGS data. While mixOmics Pro offers a specialized ecosystem for multi-omics data integration with robust statistical methodologies, Qlucore emphasizes visualization-based analysis to simplify complex data interpretation for a broader range of users.

What specific problem within precision medicine does Qlucore aim to solve with its software suite?

Qlucore aims to solve the problem of complex and time-consuming data analysis in precision medicine. Its software suite, including Qlucore Omics Explorer, Insights, and Diagnostics, is designed to accelerate, simplify, and improve research and cancer diagnostics by providing intuitive, visualization-based analysis of high-dimensional genomic and proteomic data.

Powered by ForesightIQ · Competitive intelligence from digital exhaust